Completed PHASE1 NCT00001476

Gene Therapy for Chronic Granulomatous Diseases - Long-term Follow-up

Gene Therapy Approach for Chronic Granulomatous Disease

Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Conditions Chronic Granulomatous Disease Communicable Disease

Interventions Gene Therapy Method for CGD Isolex 300i Magnetic Cell Selector

Updated 5 times since 2017 Last updated: Jun 30, 2017 Started: Jun 1, 1995 Primary completion: Dec 13, 2010 Completion: Dec 13, 2010

This PHASE1 trial investigates Chronic Granulomatous Disease and Communicable Disease and is currently completed. National Institute of Allergy and Infectious Diseases (NIAID) leads this study, which shows 5 recorded versions since 1995 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Jan 2021 — Jul 2024 [monthly]

Completed PHASE1
Jun 2018 — Jan 2021 [monthly]

Completed PHASE1
Jan 2017 — Jun 2018 [monthly]

Completed PHASE1

First recorded

Jun 1995

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

National Institute of Allergy and Infectious Diseases (NIAID)

Data source: National Institutes of Health Clinical Center (CC)

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Bethesda, United States